Company intelligence / Profile preview

Pikas

Beijing, China

Ownership: Private
Employees: ~600
Development stage: Other

Overview

PIKA rabies vaccine met primary endpoints in Phase 3 interim readout, showing superior seroconversion rate at Day 7 compared to approved comparator with favorable safety; PIKA COVID-19 vaccine received Phase 1 IND clearance.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Partnerships

New Zealand Clinical Research (NZCR)

Beyond the preview

Go deeper on Pikas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pikas.

Explore the full profile